New Integrated Data Show Promise for Novel Thyroid Eye Disease Drug

April 26, 2021

New pooled data from Phase 2 and Phase 3 clinical trials further reinforce that teprotumumab-trbw significantly improves proptosis (eye bulging) and diplopia (double vision) for thyroid eye disease (TED) in patients in different subgroups, with most maintaining a long-term response. The results were published recently in The Lancet Diabetes & Endocrinology. Teprotumumab-trbw is a fully human […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

←Researchers Develop Machine-Learning Prediction Model to Improve Medical Management of Acromegaly

Researchers Determine Best Predictors of Acromegaly Remission Following Transsphenoidal Surgery→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today